LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data
Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis
Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset
Prospective evaluation of circulating tumor DNA (ctDNA) in detecting early progression on immune checkpoint inhibitors in patients with advanced genitourinary cancers
Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)